A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer. Adding the drug enzalutamide to standard hormone therapy reduced the risk of ...

Combining enzalutamide with standard hormone therapy cut the risk of prostate cancer death by over 40% in a clinical trial The treatment targeted patients whose prostate cancer recurred aggressively ...

Ivonescimab plus chemotherapy improved PFS by 40% compared to Tevimbra in advanced squamous NSCLC, with a median PFS of 11.14 months versus 6.9 months. The study demonstrated consistent PFS benefits ...

The addition of tiragolumab to Tecentriq and Avastin did not significantly improve progression-free survival in hepatocellular carcinoma patients. Median progression-free survival was 8.3 months with ...

Roche announced positive results from the phase III evERA study evaluating investigational giredestrant in combination with everolimus in people with oestrogen receptor (ER)-positive, human epidermal ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday announced five-year follow-up results on overall survival (OS) from the Phase 3 EMPOWER-Lung 3 trial of Libtayo (cemiplimab) plus ...

Have you ever found yourself juggling multiple projects, only to realize that your team’s resources are stretched too thin or misaligned? In the fast-paced world of project management, resource ...

A two-drug combination for treating advanced kidney cancer had sustained and durable clinical benefit in more than five years of follow-up, according to a study published Aug. 1 in Nature Medicine.

Akeso, Inc., a leading biopharmaceutical company announced that the National Medical Products Administration (NMPA) has accepted the supplementary New Drug Application (sNDA) for ivonescimab ...